AsherBio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $55M

  • Investors
  • 17

AsherBio General Information

Description

Operator of a biotechnology firm intended to offer precisely targeted immunotherapies to overcome the clinical limitations of immune-based therapies. The company's immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response, offering effective and tolerable treatment for patients, enabling healthcare professionals to preferentially activate the desired immune cell types while minimizing the activation of others.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 650 Gateway Boulevard
  • Suite 100
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 650 Gateway Boulevard
  • Suite 100
  • South San Francisco, CA 94080
  • United States
+1 (650)

AsherBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AsherBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 16-Apr-2024 $55M Completed Clinical Trials - Phase 1
5. Debt - General 15-Nov-2023 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 01-Sep-2021 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 23-Mar-2021 Completed Clinical Trials - Phase 1
2. Seed Round 05-Sep-2019 $490K $640K Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 21-Aug-2019 $150K $150K Completed Clinical Trials - Phase 1
To view AsherBio’s complete valuation and funding history, request access »

AsherBio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A
Seed-3
Seed-2 362,500 $0.000010 $0.8 $0.8 1x $0.8 0.19%
Seed-1 1,050,000 $0.000010 $0.14 $0.14 1x $0.14 0.55%
To view AsherBio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AsherBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology firm intended to offer precisely targeted immunotherapies to overcome the clinical limitatio
Drug Discovery
South San Francisco, CA
22 As of 2025

Lexington, MA
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AsherBio Competitors (56)

One of AsherBio’s 56 competitors is Accent Therapeutics, a Venture Capital-Backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Accent Therapeutics Venture Capital-Backed Lexington, MA
MaveriX Oncology Venture Capital-Backed Palo Alto, CA
Alpha-9 Oncology Venture Capital-Backed Vancouver, Canada
PIPr Therapeutics Venture Capital-Backed Durham, NC
Synthekine Venture Capital-Backed Menlo Park, CA
You’re viewing 5 of 56 competitors. Get the full list »

AsherBio Patents

AsherBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4680645-A1 Fusion protein and uses thereof Inactive 17-Mar-2023
WO-2024196798-A1 Fusion protein and uses thereof Inactive 17-Mar-2023
AU-2023353978-A1 Fusions with cd8 antigen binding molecules for treating chronic viral infection Pending 29-Sep-2022
EP-4594361-A2 Fusions with cd8 antigen binding molecules for treating chronic viral infection Pending 29-Sep-2022
EP-4594361-A4 Fusions with cd8 antigen binding molecules for treating chronic viral infection Pending 29-Sep-2022 C07K14/52
To view AsherBio’s complete patent history, request access »

AsherBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AsherBio Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
AstraZeneca Corporation Minority
Bristol-Myers Squibb Corporation Minority
SNR Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
Emles Venture Partners Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

AsherBio FAQs

  • When was AsherBio founded?

    AsherBio was founded in 2019.

  • Where is AsherBio headquartered?

    AsherBio is headquartered in South San Francisco, CA.

  • What is the size of AsherBio?

    AsherBio has 22 total employees.

  • What industry is AsherBio in?

    AsherBio’s primary industry is Drug Discovery.

  • Is AsherBio a private or public company?

    AsherBio is a Private company.

  • What is the current valuation of AsherBio?

    The current valuation of AsherBio is .

  • What is AsherBio’s current revenue?

    The current revenue for AsherBio is .

  • How much funding has AsherBio raised over time?

    AsherBio has raised $219M.

  • Who are AsherBio’s investors?

    AstraZeneca, Bristol-Myers Squibb, SNR, Alexandria Venture Investments, and Emles Venture Partners are 5 of 17 investors who have invested in AsherBio.

  • Who are AsherBio’s competitors?

    Accent Therapeutics, MaveriX Oncology, Alpha-9 Oncology, PIPr Therapeutics, and Synthekine are some of the 56 competitors of AsherBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process